GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 86.28B +50.8% |
| Revenue (ttm) | 32.67B +4.1% |
| Net Income | 5.72B +122.0% |
| EPS | 1.39 +123.2% |
| Shares Out | 4.01B |
| PE Ratio | 15.49 |
| Forward PE | 11.81 |
| Dividend | 0.72 (3.32%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 8,125,558 |
| Average Volume | 9,454,614 |
| Open | 2,161.00 |
| Previous Close | 2,168.00 |
| Day's Range | 2,125.80 - 2,168.00 |
| 52-Week Range | 1,242.50 - 2,219.00 |
| Beta | 0.27 |
| RSI | 73.19 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial StatementsNews
Is GSK PLC Gaining or Losing Market Support?
GSK PLC's (NYSE: GSK) short interest as a percent of float has risen 18.92% since its last report. According to exchange reported data, there are now 17.55 million shares sold short , which is 0.88% ...
GSK's Arexvy Awaits Approval in China for RSV Prevention in Seniors
GSK's Arexvy Awaits Approval in China for RSV Prevention in Seniors
GSK’s Arexvy RSV vaccine accepted for regulatory review in China for seniors
Pharma sector stocks today, Feb 10: Pfizer rally 9%, GSK Pharma up 4.12%, Divis Laboratories rises 1.47%
The Indian pharmaceutical sector showed mixed performance on February 10, 2026, as of around 10:05 AM IST. The data provided...
GSK (GSK) Shares Climb Amid Positive Developments and EU Approval
GSK (GSK) Shares Climb Amid Positive Developments and EU Approval
GSK shares uptick for seven consecutive sessions
GSK (GSK) Gains EU Approval for Expanded Use of Nucala in COPD Treatment
GSK (GSK) Gains EU Approval for Expanded Use of Nucala in COPD Treatment
GSK wins EU nod to expand Nucala for COPD
GSK Gains European Approval for Nucala in COPD Treatment
GSK Gains European Approval for Nucala in COPD Treatment
GSK Wins EU Approval For Nucala In COPD Treatment
(RTTNews) - GSK plc (GSK) on Friday said the European Commission has approved Nucala as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD).
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT ...
GSK (GSK) Q3 2025 Earnings Call Transcript
GSK (GSK) Q3 2025 Earnings Call Transcript
3 International Stocks to Buy for 2026
Plus, which countries and sectors look most attractive to invest in today. In this bonus episode of The Morning Filter podcast, host Susan Dziubinski talks with Morningstar chief Europe markets strate...
GSK plc 2025 Q4 - Results - Earnings Call Presentation
GSK plc (GSK) Q4 2025 Earnings Call Transcript
GSK plc (GSK) Q4 2025 Earnings Call Transcript
Glaxo's new boss goes big on science - and that should be good for Britain, says ALEX BRUMMER
GlaxoSmithKline's new boss Luke Miels (pictured) is interested in addressing diseases caused by obesity, such as fibrosis of the liver.
GSK's Acquisition Highlights Trend Towards Convenience-Focused Drugs
GSK's Acquisition Highlights Trend Towards Convenience-Focused Drugs
GSK Is Eyeing $55 Billion In Sales — And It Has Nothing To Do With Obesity
GSK stock catapulted Wednesday after the UK-based drugmaker said it expects sales in five years' time to approach $55 billion.
GSK, take two: the bullish tone at the top is finally more convincing | Nils Pratley
New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential It’s a miracle. A mere 25 years after Glaxo Wellcome and SmithKline Beecham merg...
GSK PLC (GSK) Shares Up 6.49% on Feb 4
GSK PLC (GSK) Shares Up 6.49% on Feb 4
GSK PLC (GSK) Q4 2025 Earnings Call Highlights: Strong Financial Performance and Strategic ...
GSK PLC (GSK) Q4 2025 Earnings Call Highlights: Strong Financial Performance and Strategic R&D Initiatives
Q4 2025 GSK plc Earnings Call Transcript
Q4 2025 GSK plc Earnings Call Transcript
GSK beats expectations as specialist medicines drives profits in boost for new boss
GSK beat profit expectations in the fourth quarter, driven by demand for its HIV drugs and Asthma medicine.
GSK Shares Jump 5.2% as New CEO Signals Faster R&D, Deal Push
GSK Shares Jump 5.2% as New CEO Signals Faster R&D, Deal Push
GSK Stock Smashes 52-Week High On Strong Quarter, Dividend Hike
British pharmaceutical giant GSK Plc (NYSE: GSK) on Wednesday reported fourth-quarter core earnings of 68 cents (25.5 pence), outperforming the consensus forecast of 64 cents. Earnings jumped 10% or ...